Lenvatinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Cancer
Conditions
Biliary Tract Cancer
Trial Timeline
Oct 23, 2015 → Feb 27, 2019
NCT ID
NCT02579616About Lenvatinib
Lenvatinib is a phase 2 stage product being developed by Eisai for Biliary Tract Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02579616. Target conditions include Biliary Tract Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03533361 | Pre-clinical | Completed |
| NCT02211222 | Pre-clinical | Completed |
| NCT05901194 | Phase 1/2 | Active |
| NCT06138769 | Phase 2 | Active |
| NCT05171335 | Phase 2 | Recruiting |
| NCT05103904 | Phase 2 | Recruiting |
| NCT04321954 | Phase 2 | Active |
| NCT04297254 | Approved | Completed |
| NCT04447755 | Phase 2 | Completed |
| NCT04008082 | Pre-clinical | Completed |
| NCT03506048 | Phase 2 | Terminated |
| NCT03009292 | Phase 1 | Completed |
| NCT03663114 | Pre-clinical | Completed |
| NCT02846766 | Phase 2 | Withdrawn |
| NCT03433703 | Phase 2 | Terminated |
| NCT03573960 | Approved | Completed |
| NCT03168074 | Phase 2 | UNKNOWN |
| NCT02953743 | Phase 1 | Completed |
| NCT02780310 | Phase 2 | Active |
| NCT02579616 | Phase 2 | Completed |
Competing Products
20 competing products in Biliary Tract Cancer